Dirk Rades, Cansu Delikanli, Laura Doehring, Stefan Janssen, Sabine Bohnet, Elisa M Groh
{"title":"放射性肺炎的危险因素和高龄肺癌患者的预后仪器。","authors":"Dirk Rades, Cansu Delikanli, Laura Doehring, Stefan Janssen, Sabine Bohnet, Elisa M Groh","doi":"10.21873/invivo.14081","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Elderly and very elderly patients with lung cancer have a comparably high risk of radiation pneumonitis (RP). Risk scores may help to identify these patients. We have developed a risk score for very elderly patients.</p><p><strong>Patients and methods: </strong>Nine characteristics were retrospectively investigated in 21 patients aged ≥80 years for associations with symptomatic RP. Characteristics achieving significance or showing a trend were incorporated in the score, which was compared to a previous tool without age limit.</p><p><strong>Results: </strong>The incidence of RP was 33.3% and significantly associated with mean lung dose (MLD) >20 Gy. Trends were found for MLD >13 Gy and cardiovascular disease. Based on these characteristics, three risk groups were formed (2-5, 7-9, and 12 points). RP rates were 0.0%, 44.4%, and 100.0%. Positive (PPV) and negative (NPV) predictive values were both 100.0%. When using the previous score, PPV and NPV were 71.4% and 100%.</p><p><strong>Conclusion: </strong>Given the limitations of this study, the newly developed age-specific risk score appears to be a valuable tool for identifying very elderly lung cancer patients at high or low risk of radiation pneumonitis, and may offer improved predictive performance over previously established models.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2818-2823"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396045/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk Factors for Radiation Pneumonitis and a Prognostic Instrument for Very Elderly Patients With Lung Cancer.\",\"authors\":\"Dirk Rades, Cansu Delikanli, Laura Doehring, Stefan Janssen, Sabine Bohnet, Elisa M Groh\",\"doi\":\"10.21873/invivo.14081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Elderly and very elderly patients with lung cancer have a comparably high risk of radiation pneumonitis (RP). Risk scores may help to identify these patients. We have developed a risk score for very elderly patients.</p><p><strong>Patients and methods: </strong>Nine characteristics were retrospectively investigated in 21 patients aged ≥80 years for associations with symptomatic RP. Characteristics achieving significance or showing a trend were incorporated in the score, which was compared to a previous tool without age limit.</p><p><strong>Results: </strong>The incidence of RP was 33.3% and significantly associated with mean lung dose (MLD) >20 Gy. Trends were found for MLD >13 Gy and cardiovascular disease. Based on these characteristics, three risk groups were formed (2-5, 7-9, and 12 points). RP rates were 0.0%, 44.4%, and 100.0%. Positive (PPV) and negative (NPV) predictive values were both 100.0%. When using the previous score, PPV and NPV were 71.4% and 100%.</p><p><strong>Conclusion: </strong>Given the limitations of this study, the newly developed age-specific risk score appears to be a valuable tool for identifying very elderly lung cancer patients at high or low risk of radiation pneumonitis, and may offer improved predictive performance over previously established models.</p>\",\"PeriodicalId\":13364,\"journal\":{\"name\":\"In vivo\",\"volume\":\"39 5\",\"pages\":\"2818-2823\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396045/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In vivo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/invivo.14081\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Risk Factors for Radiation Pneumonitis and a Prognostic Instrument for Very Elderly Patients With Lung Cancer.
Background/aim: Elderly and very elderly patients with lung cancer have a comparably high risk of radiation pneumonitis (RP). Risk scores may help to identify these patients. We have developed a risk score for very elderly patients.
Patients and methods: Nine characteristics were retrospectively investigated in 21 patients aged ≥80 years for associations with symptomatic RP. Characteristics achieving significance or showing a trend were incorporated in the score, which was compared to a previous tool without age limit.
Results: The incidence of RP was 33.3% and significantly associated with mean lung dose (MLD) >20 Gy. Trends were found for MLD >13 Gy and cardiovascular disease. Based on these characteristics, three risk groups were formed (2-5, 7-9, and 12 points). RP rates were 0.0%, 44.4%, and 100.0%. Positive (PPV) and negative (NPV) predictive values were both 100.0%. When using the previous score, PPV and NPV were 71.4% and 100%.
Conclusion: Given the limitations of this study, the newly developed age-specific risk score appears to be a valuable tool for identifying very elderly lung cancer patients at high or low risk of radiation pneumonitis, and may offer improved predictive performance over previously established models.
期刊介绍：
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
